Akari Therapeutics Plc - Form 6-K Summary
Business Context and Reporting Period
This Form 6-K, filed on March 4, 2020, reports on a private placement of securities completed by Akari Therapeutics Plc. The offering closed in two tranches, with the initial closing on February 25, 2020, and the final closing on March 3, 2020. The transaction was executed pursuant to exemptions under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D.
Key Financial Metrics and Capital Structure
- Gross Proceeds: Approximately $9.5 million.
- Securities Issued: 5,620,296 American Depositary Shares (ADSs) at $1.70 per ADS.
- Warrants Issued: 2,810,136 unregistered warrants to purchase ADSs at an exercise price of $2.20 per ADS, expiring five years from issuance.
- Outstanding Shares Post-Closing: 28,681,598 ADSs and 2,872,895,513 ordinary shares as of March 3, 2020.
- Placement Agent Fees: 8.0% cash fee of the aggregate purchase price, plus expense reimbursement up to $50,000, a $10,000 non-accountable allowance, and 449,623 compensation warrants (8.0% of ADSs sold) at $2.55 per ADS.
The filing text does not provide specific values for revenue, net profit, operating cash flow, gross margins, or total debt levels for the reporting period.
Material Changes
The primary material change is the increase in equity capital and the dilution of existing shareholders due to the issuance of new ADSs and warrants. The company raised approximately $9.5 million to fund operations. The filing notes that the majority of investors were existing investors, including Dr. Ray Prudo, the Company's Chairman.
Outlook, Risks, and Management Commentary
Management highlighted several significant risks and uncertainties in the forward-looking statements section:
- Liquidity and Going Concern: Uncertainties regarding cash flows, the ability to meet working capital needs, and the potential need for additional capital to continue as a going concern.
- Regulatory and Clinical Risks: Delays or failures in obtaining regulatory approvals for the lead product candidate, nomacopan, and uncertainties in clinical trial results.
- Operational Risks: Difficulties in patient enrollment, reliance on third-party manufacturers for active pharmaceutical ingredients, and risks associated with the departure of former executive officers.
- Legal and IP Risks: Risks related to an ongoing SEC investigation and the ability to maintain or enforce intellectual property rights.
The company agreed to file a registration statement with the SEC by the earlier of March 26, 2020, or five trading days after filing its 2019 Form 20-F, to register the resale of the ADSs and Warrant ADSs.
Investor Verification Checklist
- Verify the company's current cash runway and burn rate to assess the sufficiency of the $9.5 million raised.
- Review the status of the ongoing SEC investigation mentioned in the risk factors.
- Confirm the timeline and progress of clinical trials for nomacopan.
- Check the effective date of the registration statement for the resale of the newly issued securities.
- Assess the impact of the warrant exercise prices ($2.20 for investors, $2.55 for the placement agent) relative to current market prices.